Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease
- 15 May 2015
- journal article
- research article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 30 (10) , 1843-1852
Abstract
The aim of this study was to evaluate the association of serum intact fibroblast growth factor 23 (FGF23) concentrations with indexed left ventricular mass in children with non-dialysis stages 3–5 of chronic kidney disease (CKD). The study cohort comprised 83 children (51 boys; mean age 12.1 ± 3.2 years) with a mean estimated glomerular filtration rate (eGFR) of 32.3 ± 14.6 ml/min/1.73 m2 who underwent clinic and ambulatory blood pressure measurement (ABPM), echocardiography and evaluation of biochemical markers of CKD-associated mineral bone disease. The mean left ventricular mass index (LVMI) was 35.9 ± 8.5 g/m2.7 (± standard deviation), with 30 (36.1 %) children showing left ventricular hypertrophy (LVH), all eccentric, as defined using age-specific criteria. For all subjects, the mean FGF23 concentration was 142.2 ± 204.4 ng/l and the normalised distribution following log transformation was 1.94 ± 0.39. There was significant univariate correlation of LVMI with GFR, body mass index (BMI) z-score and calcium intake, but not with 24-h systolic ABPM z-score, log intact parathyroid hormone or log FGF23. On multivariate analysis following adjustment for confounders, only elemental calcium content (g/kg/day) estimated from prescribed calcium-based phosphate binder dose (β = 154.9, p < 0.001) and BMI z-score (β = 2.397, p = 0.003) maintained a significant positive relationship with LVMI (model r 2 = 0.225). We observed no significant relationship of FGF23 with LVMI. Larger studies in children are needed to clarify the roles of calcium-containing phosphate binders and FGF23 with LV mass and their roles in the evolution of the development of adverse cardiovascular outcomes.Keywords
This publication has 49 references indexed in Scilit:
- Mortality Risk Among Children Initially Treated With Dialysis for End-Stage Kidney Disease, 1990-2010JAMA, 2013
- Fibroblast growth factor 23 and soluble klotho in children with chronic kidney diseaseNephrology Dialysis Transplantation, 2012
- Update on fibroblast growth factor 23 in chronic kidney diseaseKidney International, 2012
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney diseaseKidney International, 2011
- Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly populationAtherosclerosis, 2009
- Phosphate binders in CKD: chalking out the differencesPediatric Nephrology, 2009
- Age-Specific Reference Intervals for Indexed Left Ventricular Mass in ChildrenJournal of the American Society of Echocardiography, 2009
- High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patientsNephrology Dialysis Transplantation, 2009
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008